• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    solid compositions for administration, and their uses the present invention relates to solid compositions comprising a glp-1 agonist and a n- (8- (2-hydroxybenzoyl) amino) caprylic acid salt, and their use in medicine.
    公开号:BR112013014942B1
    申请号:R112013014942
    申请日:2011-12-16
    公开日:2020-01-28
    发明作者:Seier Nielsen Flemming；Sauerberg Per；Bjerregaard Simon
    申请人:Novo Nordisk As；
    IPC主号:
    专利说明:

    Invention Patent Descriptive Report for SOLID COMPOSITIONS FOR ADMINISTRATION, AND ITS USES. Field of the Invention [0001] The present invention relates to solid compositions comprising a GLP-1 agonist and an N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt and its use in medicine.
    Background of the Invention [0002] Human GLP-1 and its analogs have a low oral bioavailability. The exposure and bioavailability of human GLP-1 and its analogs are very low following oral administration. Human GLP-1 and its analogs can only be detected in plasma after oral administration if formulated with certain absorption enhancers in a specific amount. Steinert et al. (Am J Clin Nutr, Oct 2010; 92: 810 - 817) describes the oral administration of a tablet comprising GLP-1 (7-36) amide and 150 mg of N- (8- (2-hydroxybenzoyl) amino ) sodium caprylate (SNAC). WO 2010/020978 describes an oral pharmaceutical composition comprising a protein and N- (8- [2-hydroxybenzoyl) amino) caprylate (SNAC).
    [0003] There is still a need for pharmaceutical composition optimized for the oral administration of a GLP-1 agonist, such as, a GLP-1 agonist comprising a substituent.
    Summary of the Invention [0004] In some embodiments, the invention relates to a solid composition for oral administration comprising a GLP-1 agonist and a salt of caprylic N- (8- (2-hydroxybenzoyl) amino) acid, wherein a) the amount of said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is at least 0.6 mmol or at least 0.8 mmol; and b) said GLP-1 agonist is GLP-1 (7-37), GLP-1 (7-36) amide, exendin-4 or an analogue thereof, and wherein said GLP-1 agonist optionally comprises a substituent. In
    Petition 870190075717, of 06/08/2019, p. 6/57
    2/45 some embodiments the invention relates to the use of a composition as defined here in medicine.
    Description of the Invention [0005] The present invention relates to the solid compositions of a GLP-1 agonist and N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt. Surprisingly, current inventors have found that solid compositions comprising certain amounts of a salt of caprylic N- (8- (2-hydroxybenzoyl) amino) acid, such as SNAC, are ideal for the oral administration of GLP-1 agonists. In this way, the compositions provide improved exposure and / or bioavailability of the GLP-1 agonist.
    [0006] In general, the term bioavailability as used here refers to the fraction of an administered dose of an active pharmaceutical ingredient (API), such as a GLP-1 agonist as defined here, which obtains the unchanged systemic circulation . By definition, when an API is administered intravenously, its bioavailability is 100%. Anyway, when it is administered through other routines (such as orally), its bioavailability decreases (due to incomplete absorption and first-pass metabolism). Knowledge about bioavailability is important when calculating dosages for non-intravenous administration routines.
    [0007] The absolute oral bioavailability is calculated as the relative exposure of the API in the systemic circulation following oral administration (estimated as the area under the plasma concentration time curve, or AUC) in relation to the exposure of the API following intravenous administration.
    LP-1t agonist [0008] The term GLP-1 agonist as used here refers to
    Petition 870190075717, of 06/08/2019, p. 7/57
    3/45 injures the compound, which fully or partially activates the human GLP-1 receptor. In some embodiments, the GLP-1 agonist attaches to a GLP-1 receptor, for example, with an affinity constant (Kd) or activates the receptor with a power (EC50) of less than 1 μΜ, for example, lower at 100 nM as measured by methods known in the art (see, for example, WO 98/08871) and has insulinotropic activity, in which insulinotropic activity can be measured in in vivo or in vitro assays known to those of ordinary skill in the art . For example, the GLP-1 agonist can be administered to an animal with increased blood glucose (for example, obtained using an Intravenous Glucose Tolerance Test (IVGTT), a person skilled in the art should be able to determine an appropriate dosage of glucose and an adequate blood sampling regime, for example, depending on the species of the animal, for IVGTT) and the plasma insulin concentration measured over time.
    [0009] In some embodiments, the GLP-1 agonist is a GLP-1 analog, optionally comprising a substituent. The term analogous as used herein refers to a GLP-1 peptide (hereinafter peptide) means a peptide in which at least one amino acid residue of the peptide has been replaced by another amino acid residue and / or in which at least one residue of amino acid was deleted from the peptide and / or where at least one amino acid residue was added to the peptide and / or where at least one amino acid residue of the peptide was modified. Such addition or deletion of the amino acid residues can occur at the N-terminus of the peptide and / or at the C-terminus of the peptide. In some embodiments, a simple nomenclature is used to describe the GLP-1 agonist, for example, [Aib8] GLP-1 (7-37) indicates a GLP-1 analogue (7-37) in which the naturally occurring Wing in position 8 was subs
    Petition 870190075717, of 06/08/2019, p. 8/57
    4/45 replaced by Aib. In some embodiments, the GLP-1 agonist comprises a maximum of twelve, such as a maximum of 10, 8 or 6, amino acids that have been altered, for example, by substitution, deletion, insertion and / or modification, in with respect to eg GLP1 (7-37). In some embodiments, the analogue comprises up to 10 substitutions, deletions, additions and / or insertions, such as up to 9 substitutions, deletions, additions and / or inserts, up to 8 substitutions, deletions, additions and / or insertions, up to 7 substitutions, deletions , additions and / or insertions, up to 6 substitutions, deletions, additions and / or insertions, up to 5 substitutions, deletions, additions and / or insertions, up to 4 substitutions, deletions, additions and / or insertions or up to 3 substitutions, deletions, additions and / or insertions, with respect to for example, GLP-1 (737). Unless otherwise stated, GLP-1 comprises only L-amino acids.
    [00010] In some embodiments the term GLP-1 analog or GLP-1 analog as used herein refers to a peptide, or a compound, which is a variant of the human Glucagon Peptide-1 (GLP-1 (7- 37)). GLP-1 (7-37) has the sequence HAEGTFTSDV
    SSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 1). In some embodiments, the term variant refers to a compound comprising one or more amino acid substitutions, deletions, additions and / or insertions [00011] In one embodiment, the GLP-1 agonist has at least 60%, 65%, 70 %, 80% or 90% of the sequence identity for GLP-1 (7-37) over the entire length of GLP-1 (7-37). As an example of a method for determining the sequence identity between two analogs of the two peptides [Aib8] GLP-1 (737) and GLP-1 (7-37) are aligned. The identity of the [Aib8] GLP-1 (7-37) sequence relative to GLP-1 (7-37) is given by the number of identical residues aligned minus the number of different di
    Petition 870190075717, of 06/08/2019, p. 9/57
    5/45 due to the total number of residues in LPG-1 (7-37). Thus, in said example the sequence identity is (31-1) / 31.
    [00012] In one embodiment, the C-terminus of the GLP-1 agonist is an amide.
    [00013] In some embodiments, the GLP-1 agonist is GLP-1 (737) or GLP-1 (7-36) amide. In some embodiments, the GLP-1 agonist is exendin-4, the sequence which is HGEGTFITSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 2).
    [00014] In some embodiments, the GLP-1 agonist comprises a substituent that is covalently linked to the peptide. In some embodiments, the substituent comprises a fatty acid or a fatty diacid. In some embodiments, the substituent comprises a C16, C18 or C20 fatty acid. In some embodiments, the substituent comprises a C16, C18 or C20 fatty diacid. In some embodiments, the substituent comprises Formula (X)
    O (X), where n is at least 13, such as, n is 13, 14, 15, 16, 17, 18 or 19. In some embodiments, the substituent comprises Formula (X), where n is in range 13 to 19, such as, range 13 to 17. In some embodiments, the substituent comprises Formula (X), where n is 13, 15 or 17. In some embodiments, the substituent comprises Formula (X ), where n is 13. In some embodiments, the substituent comprises Formula (X), where n is 15. In some embodiments, the substituent comprises Formula (X), where n is 17. In some embodiments, the substituent comprises one or more 8-amino3,6-dioxaoctanoic acid (OEG), such as, two OEG.
    [00015] In some embodiments, the substituent is [2- (2- {2- [2- (2- {2 [(S) -4-carboxy-4- (17-carboxeptadecanoylamino) butyrylamiPetition 870190075717, of 06/08 / 2019, page 10/57
    6/45 in] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl].
    [00016] In some embodiments, the substituent is [2- (2- {2- [2- (2- {2 [(S) -4-carboxy-4 - ({trans-4 - [(19carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl].
    [00017] In some embodiments, the GLP-1 agonist is semagglutide, also known as M-epsilon26- [2- (2- {2- [2- (2- {2 - [(S) -4carboxy-4- (17-carboxeptadecanoylamino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1 (7-37), which can be prepared as described in WO 2006/097537, Example
    4.
    [00018] In some embodiments, the composition comprises the GLP-1 agonist or a pharmaceutically acceptable salt, amide, or its ester. In some embodiments, the composition comprises the GLP-1 agonist one or more pharmaceutically acceptable counterions.
    [00019] In some embodiments, the GLP-1 dosage is in the range of 0.01 mg to 100 mg. In some embodiments, the composition comprises an amount of a GLP-1 agonist in the range of 0.1 to 40 mg or 1 to 20 mg. In some embodiments, the composition comprises an amount of a GLP-1 agonist in the range of 5 to 20 mg, such as, in the range of 5 to 15 mg, such as, 5 mg, such as, 10 mg, such as, 15 mg, such as 20 mg.
    [00020] In some embodiments, the composition comprises an amount of a GLP-1 agonist in the range of 0.05 to 25 pmol, such as, in the range of 0.5 to 2.5 pmol.
    [00021] In some embodiments, the GLP-1 agonist is selected from the GLP-1 agonists mentioned in WO 93/19175, WO 96/29342, WO 98/08871, WO 99/43707, WO 99/43706, WO 99/43341, WO 99/43708, WO 2005/027978, WO 2005/058954, WO
    Petition 870190075717, of 06/08/2019, p. 11/57
    7/45
    2005/058958, WO 2006/005667, WO 2006/037810, WO 2006/037811, WO 2006/097537, WO 2006/097538, WO 2008/023050, WO 2009/030738, WO 2009/030771 and WO 2009/030774.
    [00022] In some embodiments, the GLP-1 agonist is selected from the group consisting of N-epsilon37 {2- [2- (2- {2- [2 - ((R) -
    3- carboxy-3 - {[1- (19-carboxynonadecanoyl) piperidine-4-carbonyl] amino} propionylamino) ethoxy] ethoxy} acetylamino) ethoxy] ethoxy} acetyl [desaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1 (7-37) amide; Népsilon26 {2- [2- (2- {2- [2 - ((R) -3-carboxy-3 - {[1- (19-carboxynonadecanoyl) piperidine-4-carbonyl] amino} propionylamino) ethoxy] ethoxy} acetylamino) ethoxy] ethoxy} acetyl [desaminoHis7, Arg34] GLP-1- (7-37); N-epsilon37 {2- [2- (2- {2- [2 - ((S) -3-carboxy-3 - {[1- (19carboxy-nonadecanoyl) piperidine-4carbonyl] amino} propionylamino) ethoxy] ethoxy} acetylamino) ethoxy] ethoxy} acetyl [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; Nepsilon37- [2- (2- [2- (2- [2- (2 - ((R) -3- [1- (17-carboxyptadecanoyl) piperidin-
    4-ylcarbonylamino] 3-carboxypropionylamino) ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [, DesaminoHis7, Glu22 Arg26, Arg 34, Phe (m-CF3) 28] GLP-1- (7-37) amide; N-epsilon26 - [(S) -4-carboxy-4 - ({trans-4 - [(19carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyryl] [Aib8, Arg34] GLP-1- (7-37); N-epsilon26- {4 - [(S) -4carboxy-4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] butyryl} [Aib8, Arg34] GLP-1- (737) ; N-epsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37); Nepsilon26- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4 - ({trans- 4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37) amide; N-épsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxyPetition 870190075717, from 06/08/2019, page 12/57
    8/45
    4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- ( 7-37) amide; N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino ] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4carboxy-4 - ({4 - [(trans-19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino ] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Arg26,
    Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4carboxy-4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino ] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22,
    Arg26, Arg34, Lys37] GLP-1- (7-37); N-epsilon26 [2- (2- {2- [2- (2- {2 - [(S) -4carboxy-4 - ({4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl [Aib8, Lys 26] GLP-1 (7-37) amide; N-epsilon26 [2- (2- [2- (2- [2- (2 - ((S) -2- [trans-4 - ((9carboxynonadecanoylamino] methyl) cyclohexylcarbonylamino] -4carboxybutylamino) ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8, Lys26] GLP-1 (7-37) amide; N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4carbon- 4 - ({trans-4 - [(19-carboxy-nonadecanoylamino) methyl] cyclohexanocarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Arg26, Arg34, Lys37] GLP-1- ( 7-37); N-epsilon37- [2- (2 {2- [2- (2- {2 - [(S) -4-carboxy-4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl ] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, G lu30, Arg34, Lys37] GLP-1- (7-37); N-epsilon26- [2- (2Petition 870190075717, of 8/6/2019, page 13/57
    9/45 {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {4- [4- (16- (1H-tetrazol-5-yl) hexadecanoyl sulfamoyl) butyrylamino] -butyrylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37); N-epsilon26- [2- (2 {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {12- [4- (16- (1H-tetrazole-5yl) hexadecanoyl-sulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37); N-epsilon26 [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {6- [4- (16- (1H-tetrazol-5yl) hexadecanoyl-sulfamoyl) butyrylamino] hexanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37); Népsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {4- [4- (16- (1Htetrazol-5-yl) hexadecanoylsulfamoyl ) butyrylamino] butyrylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (734); N-epsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {12- [4- (16 (1H-tetrazole-5- il) hexadecanoylsulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-34); N-epsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4carboxy-4- {6- [4- (16- (1H-tetrazol-5-yl ) hexadecanoylsulfamoyl) butyrylamino] hexanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-34); N-epsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4carboxy-4- {12- [4- (16- (1H-tetrazol-5-yl ) hexadecanoylsulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-35); Népsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {6- [4- (16- (1Htetrazol-5-yl) hexadecanoylsulfamoyl ) butyrylamino] hexanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-35); Népsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {6- [4- (16- (1Htetrazol-5-yl) hexadecanoylsulfamoyl ) butyrylamino] hexanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (736) amide; N-epsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {6- [4 (16- (1H-tetrazole-5- il) hexadecanoylsulfamoyl) butyrylami Petition 870190075717, of 08/06/2019, page 14/57
    10/45 in] hexanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8,
    Arg34] GLP-1- (7-35); N-epsilon26- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4carboxy-4- {12- [4- (16- (1H-tetrazol-5-yl ) hexadecanoyl sulfamoyl) butyrylamino] dodecanoylamino} butyryl-amino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Lys33, Arg34] GLP-1- (7-34); N-epsilon26- [2- (2- {2 [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {12- [4- (16- (1H-tetrazol-5yl) hexadecanoylsulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-
    36) amide; N-epsilon26- [2- (2- {2- [2- (2- {2- [2- (2- {2- [2- (2- {2- [2- (2- {2- [ 2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {12- [4- (16- (1H-tetrazol-5yl) hexadecanoyl sulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] epoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetylamin o] ethoxy} ethoxy) acetylamino] ethoxy} Eoxy] Argyl] L, [E34] GLP-1 (7-36) amide; N-epsilon37- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4 {12- [4- (16- (1H-tetrazole-5- il) hexadecanoylsulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37- [2- (2- {2 - [(S) -4carboxy-4 - ((S) -4-carboxy-4- {12- [4- (16- (1H-tetrazol-5yl) hexadecanoylsulfamoyl ) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37 {2- [2- (2- {2- [2 - ((R) -3-carboxy-3 {[1- (19-carboxy-nonadecanoyl) piperidine-4carbonyl] amino} propionylamino) ethoxy] ethoxy } acetylamino) ethoxy] ethoxy} acetyl [desaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1 (7-
    37) amide; N-épsilon37 {2- [2- (2- {2- [2 - ((S) -3-carboxy-3 - {[1- (19-carboxinonadecanoyl) piperidine-4-carbonyl] amino} propionylamino) ethoxy] ethoxy} acetylamino) ethoxy] ethoxy} acetyl [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37- [2- (2- [2- (2- [2- (2 - ((R) -3- [1- (17carboxiepta-decanoyl) piperidin-4-ylcarbonylamino] 3-carboxyPetition 870190075717, from 06 / 08/2019, page 15/57
    11/45 propionylamino) ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, Arg34, Phe (m-CF3) 28] GLP-1- (7-37) amide; Nepsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino ] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4 ({trans-4 - [(19-carboxy-nonadecanoylamino) methyl] cyclohexane- carbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37 [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37); N-epsilon37 [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4 - ({trans-4 - [(19-carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, Glu30, Arg34, Lys37] GLP-1- (7-37); Nepsilon37- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) -4-carboxy-4- {12- [4- (16- (1Htetrazol-5-yl) hexadecanoyl -sulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37- [2- (2- {2 - [(S) -4-carboxy-4 - ((S) 4-carboxy-4- {12- [4- (16- (1H-tetrazole-5- il) hexadecanoylsulfamoyl) butyrylamino] dodecanoylamino} butyrylamino) butyrylamino] ethoxy} ethoxy) acetyl] [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; Nepsilon37- (3 - ((2- (2- (2- (2- (2-Hexadecyloxyethoxy) ethoxy) ethoxy) ethoxy) ethoxy)) propionyl) [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1 (7 -37) amide; N-epsilon37- {2- (2- (2- (2- [2- (2- (4- (hexadecanoylamino) -4carboxybutyryl-amino) ethoxy) ethoxy] acetyl) ethoxy) ethoxy) acetyl)} [desaminoHis7, Glu22 , Arg26, Glu30, Arg34, Lys37] GLP-1- (737) amide; N-épsilon37- {2- (2- (2- (2- [2- (2- (4- (hexadecanoylamino) -4Petition 870190075717, from 06/08/2019, p. 16/57
    12/45 carboxy-butyryl-amino) ethoxy) ethoxy] acetyl) ethoxy) ethoxy) acetyl)} [desaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; Nepsilon 37- (2- (2- (2- (2- (2- (2- (2- (2- (2- (octadecanoyl-amino) ethoxy) ethoxy) acetylamino) ethoxy) ethoxy) acetylamino) ethoxy) acetyl) [desaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1 (7-37) amide; N-epsilon37- [4- (16 (1H-Tetrazol-5-yl) hexadecanoyl sulfamoyl) butyryl] [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37) amide; N-epsilon37- [2- (2- {2- [2- (2- {2 [(S) -4-carboxy-4- (19-carboxynonadecanoylamino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl ] [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37); N-epsilon37- (2- {2- [2 - ((S) -4-carboxy-4 - {(S) 4-carboxy-4 - [(S) -4-carboxy-4- (19-carboxynonecanoylamino)) butyrylamino] butyrylamino} butyrylamino) ethoxy] ethoxy} acetyl) [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37); Népsilon37- {2- [2- (2 - {(S) -4 - [(S) -4- (12- {4- [16- (2-tert-Butyl-2H-tetrazol-5-yl) hexadecanoylsulfamoyl ] butyrylamino} dodecanoylamino) -4-carboxybutyrylamino] -4-carboxybutyrylamino} ethoxy) ethoxy] acetyl} [DesaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1 (737); N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4- (17-carboxy-heptadecanoylamino) -butyrylamino] -ethoxy} -ethoxy) -acetylamino] -ethoxy} ethoxy) -acetyl] [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- (7-37); Nalfa37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4- (17-carboxy-heptadecanoylamino) -butyrylamino] -ethoxy} -ethoxy) -acetylamino] -ethoxy } ethoxy) -acetyl] [Aib8, Glu22, Arg26, Arg34, epsilon-Lys37] GLP-1- (737) peptide; N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4- (17-carboxy-heptadecanoylamino) -butyrylamino] -ethoxy} -ethoxy) -acetylamino] -ethoxy} ethoxy) -acetyl] [desaminoHis7, Glu22, Arg26, Arg34, Lys37] GLP-1- (737); N-epsilon36- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxy-4- (15-carboxydentanecanoylamino) -butyrylamino] -ethoxy} -ethoxy) -acetylamino] -ethoxy} ethoxy) -acetyl] [desaminoHis7, Glu22, Arg26, Glu30, Arg34, Lys36] GLP1- (7-37) -Glu-Lys peptide; N-épsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4-carboxyPetition 870190075717, from 08/06/2019, page 17/57
    13/45
    4 - ({trans-4 - [(19carboxynonadecanoylamino) methyl] cyclohexanecarbonyl} amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [Aib8, Glu22, Arg26, Arg34, Lys37] GLP-1- (7- 37); N-epsilon37- [2- (2- {2- [2- (2- {2 - [(S) -4carboxy-4- (17-carboxy-heptadecanoylamino) -butyrylamino] -ethoxy} -etoxy) acetylamino] - ethoxy} -ethoxy) -acetyl] - [Aib8, Glu22, Arg26, Arg34, Aib35, Lys37] GLP-1- (7-37); N-epsilon37 - [(S) -4-carboxy-4- (2- {2- [2- (2- {2- [2- (17carboxeptadecanoylamino) ethoxy] ethoxy} acetylamino) ethoxy] ethoxy} acetylamino) butyryl] [Aib8, Glu22, Arg26, 34, Lys37] GLP-1 (7-37); Nepsilon37- [2- (2- [2- (2- [2- (2- [4- (17-carboxeptadecanoylamino) -4 (S) carboxybutyramino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [ ImPr7, Glu22, Arg26, 34, Lys37], GLP-1- (7-37); N-épsilon26- {2- [2- (2- {2- [2- (2 {(S) -4-carboxy-4- [10- (4-carboxyphenoxy) decanoylamino] butyrylamino} ethoxy) ethoxy] acetylamino} ethoxy) ethoxy] acetyl}, N-epsilon37 {2- [2- (2- {2- [2- (2 - {(S) -4-carboxy-4- [10- (4-carboxy-phenoxy) decanoylamino ] butyrylamino} ethoxy) ethoxy] acetylamino} ethoxy) ethoxy] acetyl} - [Aib8, Arg34, Lys37] GLP-1 (7-37) -OH; N-epsilon26 (17-carboxyepta-decanoyl) - [Aib8, Arg34] GLP-1- (7-37) -peptide; N-epsilon26- (19-carboxynonadecanoyl) [Aib8, Arg34] GLP-1- (7-37); N-epsilon26- (4 - {[N- (2-carboxyethyl) -N- (15carboxypenta-decanoyl) amino] methyl} benzoyl [Arg34] GLP-1- (7-37); Népsilon26- [2- (2- [2- (2- [2- (2- [4- (17-carboxeptadecanoylamino) -4 (S) carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7 -37); N-epsilon26- [2- (2- [2- (2- [2- (2- [4- (19carboxynonadecanoylamino) -4 (S) -carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37); N-epsilon26- [2- (2 [2- (2- [2- (2- [4- (17-carboxeptadecanoylamino) -4 (S ) carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [3- (4Imidazolyl) Propionyl7, Arg34] GLP-1- (7-37); N-epsilon26- [2- (2- [2- (2 - [2- (2 [4- (17-carboxeptadecanoylamino) - ((carboxymethylamino) acetylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8,
    Petition 870190075717, of 06/08/2019, p. 18/57
    14/45
    Arg34] GLP-1- (7-37); N-epsilon26- [2- (2- [2- (2- [2- (2- [4- (17carboxeptadecanoylamino) -3 (S) Sulfopropionylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37); N-epsilon26- [2- (2- [2- (2- [2- (2- [4- (17carboxeptadecanoylamino) -4 (S) carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Gly8, Arg34] GLP-1- (7-37); N-epsilon26- [2- (2- [2- (2- [2- (2- [4- (17carboxeptadecanoylamino) -4 (S) carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37) -amide; N-epsilon26- [2- (2- [2- (2- [2- (2- [4- (17carboxeptadecanoylamino) -4 (S) carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8,
    Arg34, Pro37] GLP-1- (7-37) amide; Aib8, Lys26 (N-epsilon26- {2- (2- (2- (2 [2- (2- (4- (pentadecanoylamino) -4carboxybutyrylamino) ethoxy) ethoxy] acetyl) ethoxy) ethoxy) acetyl)}), Arg34 ) GLP-1 H (7-37) -OH; N-epsilon26- [2- (2- [2- (2- [2- (2- [4 - {[N- (2-carboxyethyl) -N- (17carboxieptadecanoyl) amino] methyl} benzoyl) amino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8, Arg34] GLP-1 (7-37); N-alpha7formyl, N-epsilon26- [2- (2- [2- (2- [2- (2- [4- (17-carboxyptadecanoyl-amino) 4 (S) -carboxy-butyrylamino] ethoxy) ethoxy] acetylamino ) ethoxy] ethoxy) acetyl] [Arg34] GLP-1- (7-37); N-épsilon2626- [2- (2- [2- (2- [2- (2- [4- (17carboxeptadecanoylamino) -4 (S) -carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8 , Glu22,
    Arg34] GLP-1- (7-37); N-épsilon26 {3- [2- (2- {2- [2- (2- {2- [2- (2- [4- (15- (N ((S) -1,3-dicarboxypropyl) carbamoyl ) pentadecanoylamino) - (S) -4carboxybutyrylamino] epoxy) epoxy] epoxy} ethoxy) epoxy] ethoxy} ethoxy) ethoxy] propionyl} [Aib8, Arg34] GLP-1- (7-37); Népsilon26- [2- (2- [2- (2- [2- (2- [4 - {[N- (2-carboxyethyl) -N- (17-carboxyheptadecanoyl) amino] methyl} benzoyl) amino] (4 (S) -carboxybutyrylamino) epoxy) epoxy] acetylamino) epoxy] epoxy) acetyl] [Aib8, Arg34] GLP-1 (7Petition 870190075717, of 06/08/2019, page 19/57
    15/45
    37); N-epsilon26 - {(S) -4-carboxy-4 - ((S) -4-carboxy-4 - ((S) -4-carboxy-4 ((S) -4-carboxy-4- (19- carboxynonadecanoylamino) butyrylamino) butyrylamino) butyrylamino) butyrylamino} [Aib8, Arg34] GLP-1- (7-37); N-epsilon26-4- (17-carboxyptadecanoylamino) -4 (S) -carboxybutyryl- [Aib8, Arg34] GLP-1- (7-37); N-epsilon26- {3 [2- (2- {2- [2- (2- {2- [2- (2- [4- (17-carboxeptadecanoylamino) -4 (S) carboxybutyrylamino] ethoxy) ethoxy] ethoxy } ethoxy) ethoxy] ethoxy} ethoxy) ethoxy] propionyl} [Aib8, Arg34] GLP-1- (7-37); Nepsilon26- {2- (2- (2- (2- [2- (2- (4- (17-carboxeptadecanoylamino) -4carboxybutyrylamino) ethoxy) ethoxy] acetyl) ethoxy) ethoxy) acetyl)} [Aib8,22,27 , 30.35, Arg34, Pro37, Lys26] GLP-1 (7-37) amide; Nepsilon26- [2- (2- [2- [4- (21-carboxyuneicosanoylamino) -4 (S) carboxybutyrylamino] ethoxy] ethoxy) acetyl] [Aib8, Arg34] GLP-1- (7-37); and Népsilon26- [2- (2- [2- (2- [2- (2- [4- (21-carboxyuneicosanoylamino) -4 (S) carboxybutyrylamino] ethoxy) ethoxy] acetylamino) ethoxy] ethoxy) acetyl] [Aib8 ,
    Arg34] GLP-1- (7-37).
    Release agent: N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt [00023] The release agent employed in the present invention is a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid. The structural formula of N- (8- (2-hydroxybenzoyl) amino) caprylate is shown in Formula (I).
    OH (I) [00024] In some embodiments, the N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt comprises a monovalent cation, two monovalent cations or a divalent cation. In some embodiments, the N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is selected from the group consisting of the sodium salt, potassium salt and
    Petition 870190075717, of 06/08/2019, p. 20/57
    16/45 N- (8- (2-hydroxybenzoyl) amino) caprylic acid calcium salt.
    [00025] N- (8- (2-hydroxybenzoyl) amino) caprylate salts can be prepared using the method described in, for example, WO 96/030036, WO 00/046182, WO 01/092206 or WO 2008/028859 .
    [00026] The N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt can be crystalline and / or amorphous. In some embodiments, the release agent comprises anhydrate, monohydrate, dihydrate, trihydrate, a solvate or a third of a hydrate of the caprine N- (8- (2-hydroxybenzoyl) amino) acid salt as well as combinations thereof. In some embodiments, the release agent is an N (8- (2-hydroxybenzoyl) amino) caprylic acid salt as described in WO 2007/121318.
    [00027] In some embodiments, the release agent is sodium N- (8- (2-hydroxybenzoyl) amino) caprylate (referred to here as SNAC), also known as sodium 8- (salicyloylamino) octanoate.
    [00028] In some embodiments, the amount of the N (8- (2-hydroxybenzoyl) amino) caprylic acid salt in the composition is at least 0.6 mmol, as selected from the group consisting of at least 0, 65 mmol, at least 0.7 mmol, at least 0.75 mmol, at least 0.8 mmol, at least 0.8 mmol, at least 0.9 mmol, at least 0.95 mmol and at least 1 mmol. In some embodiments, the amount of the N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt in the composition is in the range of 0.6 to 2.1 mmol or 0.6 to 1.9 mmol. In some embodiments, the amount of the N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt in the composition is in the range of 0.7 to 1.7 mmol or 0.8 to 1.3 mmol. In some embodiments, the amount of the N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt in the composition is up to 2.1 mmol, as selected from the group consisting of up to 2.1 mmol, up to 2 mmol, up to 1.9 mmol, up to 1.8 mmol, up to 1.7 mmol, up to 1.6 mmol, up to 1.5 mmol, up to 1.4 mmol, up to 1.3 mmol,
    Petition 870190075717, of 06/08/2019, p. 21/57
    17/45 up to 1.2 mmol and up to 1.1 mmol. In some embodiments, the amount of the N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is 1 mmol, such as 1.08 mmol.
    [00029] In some embodiments, the amount of SNAC in the composition is at least 175 mg, such as, an amount selected from the group consisting of at least 200 mg, at least 210 mg, at least 220 mg, at least 230 mg, at least 240 mg, at least 250 mg, at least 260 mg, at least 270 mg and at least 280 mg. In some embodiments, the amount of SNAC in the composition is in the range of 175 to 575 mg, such as 200 to 500 mg or 250 to 400 mg. In some embodiments, the amount of SNAC in the composition is up to 575 mg, such as, an amount selected from the group consisting of up to 550 mg, up to 525 mg, up to 500 mg, up to 475 mg, up to 450 mg, up to 425 mg, up to 400 mg, up to 375 mg, up to 350 mg and up to 325 mg. In some embodiments, the amount of SNAC in the composition is 300 mg.
    [00030] In some embodiments, the molar ratio between the GLP-1 agonist and the release agent in the composition is less than 10, such as, less than 5 or less than 1.
    Composition [00031] The composition of the present invention is a solid composition and is administered orally.
    [00032] In some embodiments, the composition comprises at least one pharmaceutically acceptable excipient. The term excipient as used herein refers widely to any component other than the active therapeutic ingredient (s). The excipient can be an inert substance, an inactive substance, and / or a substance that is not medically active. The excipient can serve several purposes, for example, as a carrier, vehicle, filler, binder, lubricant, sliding agent, disintegrating agent,
    Petition 870190075717, of 06/08/2019, p. 22/57
    18/45 flow control agents, crystallization retardants, solubilizers, stabilizers, dyes, flavors, surfactants, emulsifiers and / or to improve the administration, and / or the absorption of the active substance. A person skilled in the art can select one or more of the above-mentioned excipients with respect to the particular desired properties of the solid oral dosage form by routine experimentation and without undue overload. The amount of each excipient used can vary within ranges conventional in the art. The techniques and excipients that may be used to formulate oral dosage forms are described in Handbook of Pharmaceutical Excipients, 6th edition, Rowe and other Eds., American Pharmaceuticals Association and The Pharmaceutical Press, publications department of the Royal Pharmaceutical Society of Great Britain (2009), and Remington: the Science and Practice of Pharmacy, edition 21, to Gennaro, Ed, Lippincott Williams & Wilkins (2005) .. In some embodiments of the excipients, they can be selected from binders, such as polyvinyl pyrrolidone ( povidone), etc., fillers such as powdered cellulose, microcrystalline cellulose, cellulose derivatives such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose, dibasic calcium phosphate, corn starch, pregelatinized starch, etc., lubricants and / or glidants such as stearic acid, magnesium stearate, sodium stearyl fumarate, glycerol tribehenate, etc., flow control agents such as colloidal silica, talc, etc; crystallization retardants, such as Povidone, etc., solubilizers, such as Pluronic, povidone, etc., coloring agents, including dyes and pigments such as red or yellow iron oxide, titanium dioxide, talc, etc., pH control agents such such as citric acid, tartaric acid, fumaric acid, sodium citrate, calcium dibasic phosphate, sodium dibasic phosphate, etc., surfactants and emulsifiers, such as Pluronic, polyethylene glycols,
    Petition 870190075717, of 06/08/2019, p. 23/57
    19/45 sodium carboxymethyl cellulose, and hydrogenated polyethoxylated Hy castor oil, etc., and mixtures of two or more of these excipients and / or adjuvants.
    [00033] In some embodiments, the composition comprises at least 60% (w / w) delivery agent, less than 10% (w / w) binder, 5-40% (w / w) filler, and less than 10% (w / w) lubricant or sliding agent.
    [00034] In some embodiments, the composition comprises at least 60% (w / w), such as at least 70% (w / w) or at least 75% (w / w), delivery agent.
    [00035] In some embodiments, the composition comprises 0.1-10% (w / w), such as 0.2-4% (w / w) or 0.5-3% (w / w), of the binder. In some embodiments, the composition comprises 1% (w / w) or 2% (w / w) of the binder. The composition may comprise a binder, such as povidone, starches, celluloses and their derivatives, such as microcrystalline cellulose, for example, AVICEL PH from FMC (Phila-delphia, PA), hydroxypropylcellulose and hydroxylethyl cellulose METHOCEL hydroxyl-ylpropylmethyl cellulose from Dow Chemical Corp (Midland, MI); sucrose, dextrose, corn syrup, polysaccharides, and gelatin. The binder can be selected from the group consisting of dry binders and / or wet granulated binders. Suitable dry binders are, for example, cellulose powder and microcrystalline cellulose, such as Avicel PH 102 and Avicel PH 200. In some embodiments, the composition comprises Avicel, such as Avicel PH 102. Binders suitable for wet or granular granulation dry granulation are corn starch, polyvinylpyrrolidone (povidon), vinylpyrrolidone-vinyl acetate copolymer (copovidone), and cellulose derivatives such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose. In some embodiments, the composition comprises povidone.
    Petition 870190075717, of 06/08/2019, p. 24/57
    20/45 [00036] In some embodiments, the composition comprises 540% (w / w), such as 10-30% (w / w) or 5-25% (w / w), filler. In some embodiments the composition comprises 10.9% (w / w) or 18% (w / w) of filler material, or comprises 19.5% (w / w) or 20.5 (w / w) filler . The filling material can be selected from lactose, mannitol, erythritol, sucrose, sorbitol, calcium phosphate, such as calciumhydrogen phosphate, microcrystalline cellulose, powdered cellulose, powdered sugar, compressible sugar, dextrates, dextrin and dextrose . In some embodiments, the composition comprises microcrystalline cellulose, such as Avicel PH 102 or Avicel PH 200.
    [00037] In some embodiments, the composition comprises 0.1-10% (w / w) or 0.5-5% (w / w), such as 1-3.5% (w / w) or 1 % (w / w), of lubricant and / or a sliding agent. In some embodiments, the composition comprises a lubricant and / or a sliding agent, such as talc, magnesium stearate, calcium stearate, zinc stearate, glyceryl ser-henate, polyethylene oxide polymers, sodium lauryl sulfate, lauryl sulfate magnesium, sodium oleate, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oils, silicon oxide and / or polyethylene glycol. In some embodiments, the composition comprises magnesium stearate.
    [00038] In some embodiments, the composition comprises a disintegrating agent, such as sodium starch glycolate, potassium polacrylin, sodium starch glycolate, crospovidon, croscarmellose, sodium carboxymethyl cellulose or dry corn starch.
    [00039] The composition can comprise one or more surfactants, for example a surfactant, at least one surfactant, or two different surfactants. The term surfactant refers to all molecules or ions, which are made up of a water-soluble part (hydrophilic) and a fat-soluble part (lipophilic). The surfactant can,
    Petition 870190075717, of 06/08/2019, p. 25/57
    21/45 for example being selected from the group consisting of anionic surfactants, cationic sur-factants, non-ionic surfactants, and / or zwitterionic surfactants.
    [00040] Still further, the composition can be formulated as is known in the art of oral formulations of insulinotropic compounds, e.g. using any one or more of the formulations described in WO 2008/145728.
    [00041] The composition can also be used in the formulation of specific, controlled, sustained, prolonged and prolonged, delayed, pulsatile, delayed, and / or slow release drug delivery systems.
    [00042] The composition of the invention can be prepared as it is known in the art.
    [00043] The composition can be administered in various dosage forms, for example, as a tablet, a coated tablet, a chewing gum, a capsule, such as hard or soft gelatin capsules or a powder. The composition can further be compounded in a drug carrier or drug delivery system, for example, in order to improve stability and / or solubility or to further improve bioavailability. The composition can be a freeze-dried or spray-dried composition.
    [00044] The composition can be in the form of a tablet. In some embodiments the weight of the tablet is in the range of 175 mg to 1000 mg, as in the range of 175-250 mg, 300-500 mg and 500-900 mg, or as about 200 mg, about 400 mg or about 700 mg. In some embodiments, the weight of the tablet is in the range of 200 mg to 1000 mg, such as in the range of 500-700 mg and 600-1000 mg, or such as about 200 mg, about 400 mg, about 600 mg or about 800 mg.
    [00045] In some embodiments, the composition can be granular
    Petition 870190075717, of 06/08/2019, p. 26/57
    22/45 before being compacted. The composition can comprise an intragranular part and an extragranular part, where the intragranular part has been granulated and the extragranular part has been added after granulation. The intra-granular part can comprise the GLP-1 agonist, the delivery agent and a linker. In some embodiments, the intragranular part comprises povidone. The extragranular part may comprise a filler, a lubricant and / or a glidant. In some embodiments of the extragranular part it comprises microcrystalline cellulose, such as Avicel, for example avicel PH120 or avicel PH200. In some embodiments the extragranular part comprises magnesium stearate.
    [00046] To prepare a dry mixture of tablet forming material, the various components are weighed, and then optionally delumped combined. The mixing of the components can be carried out until a homogeneous mixture.
    [00047] If the granules are to be used in the tablet material, granules can be produced in a manner known to a person skilled in the art, for example using known wet granulation methods for the production of compound granules or broken granules. Methods for the formation of built-up granules can operate continuously and include, for example, the simultaneous spraying of the granulation mass with the granulation and drying solution, for example in a granulator drum, in pot granulators, in disc mills, in a fluidized bed, by spray drying or solidifying spray, or to operate in a batch manner, for example in a fluidized bed, in a rotating fluidized bed, in a batch mixer, such as a high-shear mixer or a low-shear mixer or in a spray drying drum. Methods for the production of broken granules, which can be carried out in
    Petition 870190075717, of 06/08/2019, p. 27/57
    23/45 discontinuous form and in which the granulation mass first forms a wet aggregate with the granulation solution, which is subsequently crushed or by other means formed into granules of the desired size and the granules can then be dried. Suitable equipment for the granulation stage are planetary mixers, low shear mixers, high shear mixers, extruders and spheronizers, such as a Loedige appliance companies, Glatt, Diosna, Fielder, Collette, Aeschbach, Alexanderwerk, Ytron, Wyss & Probst, Werner & Pfleiderer, HKD, Loser, Fuji, Nica, Caleva and Gabler. Granules can also be formed using dry granulation techniques in which the pharmaceutically active agent is compressed with excipients to form relatively large molds, for example, slugs or tapes, which are comminuted by grinding, and the soil material it serves as the tabletting material to be later compacted. Equipment suitable for dry granulation is a Gerteis roller compaction equipment, such as Gerteis MINI-PACTOR.
    [00048] To compress the tablet forming material into a solid oral dosage form, for example a tablet, a tablet press can be used. In a tablet press, the tablet forming material is filled (for example, gravity fed or fed) in a molding cavity. The tablet-forming material is then compacted by a pressure punch. Thereafter, the compact result-ing or tablet is ejected from the tablet press. The aforementioned compaction process is hereinafter referred to here as process compaction. Suitable tablet presses include, but are not limited to, tablet presses and eccentric rotary tablet presses. Examples of tablet presses include, but are not limited to, the
    Petition 870190075717, of 06/08/2019, p. 28/57
    24/45
    Fette 102i (Fette GmbH), Korsch XL100, Korsch PH 106 rotary tablet press (Korsch AG, Germany), EK-S Korsch eccentric tablet press (Korsch AG Germany) and Manesty F-Press (Manesty Ma-chines Ltd ., UK).
    [00049] In some embodiments of the method of preparing the tablet with prisons a) wet granulation of a mixture comprising the GLP-1 agonist, the inter-agent agent and a binder, b) optionally, drying the wet granulate, c) mixing the dried wet granules with at least one filler and at least one lubricant or a sliding agent and then
    d) compressing the mixture into tablets. The granulation can be a wet granulation or a dry granulation.
    [00050] The disintegration time: In some modalities the disintegration time of the tablet is in the range of 7 minutes to 15 minutes, as well as in the range of 8 minutes to 13 minutes. The disintegration time can be determined using a Pharma PTZ AUTO disintegration tester. The disintegration device consists of a rack basket that holds 2 x 6 plastic tubes, open at the top and bottom, the bottom of the tube is covered by a screen. The tablets are placed inside the tubes and disintegrating discs are placed on top of the tablets for automatic detection. The basket is immersed in 800 mL of purified water, kept at 37 ° C, in a 1L beaker. Time to complete disintegration is measured. In addition, the tablets can be observed visually for the behavior surface to erode during the disintegration test.
    [00051] In some embodiments, the tablet of the invention co-distributes the active ingredients and the delivery agent by surface erosion, so the tablets become smaller and smaller, with the time of dissolution, mainly from the surface of
    Petition 870190075717, of 06/08/2019, p. 29/57
    25/45 tablets did not disintegrate. Simultaneous release: In some embodiments, the compositions show the concomitant release of the GLP-1 agonist and the delivery agent from the surface of the tablet. This can be tested by visual inspection during the disintegration test, the tablets do not have the concomitant release of GLP-1 agonist and the delivery agent from the surface of the tablet, the tablet breaks into two smaller parts during the first 8 minutes of test disintegration.
    [00052] Dissolution test: Another test for the simultaneous release of the GLP-1 agonist and the delivery agent is the dissolution test. Here, the bright aspect ratio (in percent) of the GLP-1 agonist and the delivery agent is measured. The dissolution test can be performed, as described in the following: dissolution is performed on a Varian 705 DS. The analysis is based on the pharmaco-Peia Ph Eur 2.9.3 method, Apparatus 2 (Paddle apparatus). 100 mL of mini-pot with mini-paddles is used, and the paddle speed is 75 rpm. After 120 minutes, the speed of the paddle is changed to 250 rpm. The dissolution medium used for the dis-solution assay is 100 mL of 200 mM KH2PO4 (containing 0.07% Tween 80, to prevent the GLP-1 agonist from sticking to the bathroom wall and the spade) , with pH 6.8. Samples are taken after 5, 15, 30, 45, 60, 120 and 135 minutes. The sample volume is 2 mL, and the sample is made with a disposable syringe. After each sample is taken, the same volume (2 mL) of the dissolution medium is added to the bath, in order to maintain the total volume of 100 mL of constant. The sample is pressed through a 0.22 Millex ® mM-GV filter. Finally, the samples are analyzed for the concentration of the GLP-1 agonist and for the concentration of the delivery agent by UPLC.
    [00053] Hardness Test: The hardness of the tablets is measured with a Pharma test (33AA02), which measures the strength required to break down 870190075717, of 06/08/2019, pg. 30/57
    26/45 per tablet, and the assay is based on the Ph Eur pharmacopoeia method. 2.9.8.
    [00054] Treatment with a composition according to the present invention can also be combined with one or more additional pharmacologically active substances, for example selected from anti-diabetic agents, anti-obesity agents, appetite regulating agents, agents antihypertensives, agents for the treatment and / or prevention of complications resulting from or associated with diabetes and agents for the treatment and / or prevention of complications and disorders resulting from or associated with obesity. Examples of these pharmacologically active substances are: insulin, sulfonylureas, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV), inhibitors of liver enzymes involved in stimulating gluconeogenesis and / or glycogenolysis, a glucose uptake in modulators, compounds that alter lipid metabolism, such as antihyperlipidemic agents such as HMG CoA inhibitors (statins), gastric inhibitor polypeptides (GIP analogs), food intake reduction compounds, RXR agonists and agents that act on the ATP-dependent potassium channel of β-cells; Cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextropropoxyphene, neteglinide, repaglinide; β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE inhibitors (angiotensin converting enzyme), such as benazepril, captopril, enalapril, fosinopril, lisinopril, alatriopril, quinapril and ramipril channel blockers, such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and blockers, such as doxazosin, urapidil, prazosin and terazosin; CART (cocaine amphetamine transcription) agonists, regulated neuropeptide Y (NPY) antagonists, PYY agonists, receptor agonists
    Petition 870190075717, of 06/08/2019, p. 31/57
    27/45 tor Y2, Y4 receptor agonits, mixed Y2 / Y4 agonists, MC4 (melanocortin 4), orexin agonists, TNF (tumor necrosis factor) antagonists, CRF (corticotropin releasing factor) agonists, CRF BP (factor F corticotropin binding protein releasing) antagonists, urocortin β 3 agonists, oxyntomodulin and analogues, MSH agonists (melanocyte stimulating hormone), MCH (melanocyte-concentration hormone) CCK antagonists (cholecystokinin) agonists, serotonin reuptake inhibitors, serotonin reuptake noradrenaline reuptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, agonists, bombesin galanin antagonists, growth hormone, growth hormone, releasing TRH (thyrotropin releasing hormone) agonist compounds, UCP 2 or 3 (decoupling proteins 2 or 3) modulators, leptin agonists, DA agonists (bromocriptine, doprexin), lipase / amylase inhibitors, R XR (retinoid X receptor) modulators, TR β agonists, histamine H3 antagonists, gastric polypeptide agonists or analogue antagonist (GIP) inhibitors, gastrin and gastrin analogs.
    [00055] Other embodiments of the compositions of the invention are described in the section entitled specific embodiments, before the experimental section.
    Pharmaceutical indications [00056] The present invention also relates to a composition of the invention for use as a medicament. In particular modalities of the composition of the invention, they can be used for the following medical treatments, preferably all relating to one form or another of diabetes:
    (I) the prevention and / or treatment of all forms of diabetes, such as hyper-perglycemia, type 2 diabetes, glucose tolerance, type 1 diabetes, non-insulin dependent diabetes, MODY (di
    Petition 870190075717, of 06/08/2019, p. 32/57
    28/45 young adults), GES- gestational diabetes, and / or for the reduction of HbA1C;
    (Ii) to delay or prevent the progression of diabetic disease, such as the progression of type 2 diabetes, delaying the progression of impaired glucose tolerance (IGT) requiring insulin for type 2 diabetes, and / or delaying the progression of not requiring insulin for type 2 diabetes insulin requiring type 2 diabetes;
    (Iii) improve β-cell function, such as reducing β-cell apoptosis, increasing β-cell function and / or β-cell mass, and / or to restore glucose sensitivity to β-cells ;
    (Iv) the prevention and / or treatment of cognitive disorders;
    (V) the prevention and / or treatment of eating disorders, such as obesity, for example, by decreasing food intake, reducing body weight, suppressing appetite, inducing satiety, treating or preventing binge eating disorder, bulimia nervosa and / or obesity induced by administration of an antipsychotic agent or a steroid, reduced gastric motility and / or delayed gastric emptying;
    (Vi) the prevention and / or treatment of diabetic complications, such as neuropathy, including peripheral neuropathy, nephropathy, or retinopathy;
    (Vii) improvement of lipid parameters, such as the prevention and / or treatment of dyslipidemia, lowering total serum lipids, HDL reduction, small reduction, dense LDL, VLDL reduction: decreased triglycerides; decrease HDL cholesterol, increase, decrease plasma levels of lipoprotein A (Lp (a)) in a human being; inhibiting the generation of an apolipoprotein (apo (a)) in vitro and / or in vivo;
    (Iix) in the prevention and / or treatment of cardiovascular diseases, such as syndrome X, atherosclerosis, myocardial infarction,
    Petition 870190075717, of 06/08/2019, p. 33/57
    29/45 coronary heart disease, stroke, cerebral ischemia, heart disease or early cardiovascular onset, such as left ventricular hypertrophy, coronary artery disease; essential hypertension; acute hypertensive emergency, cardiomyopathy, heart failure, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syn-copy; atheroschlerosis, mild chronic heart failure, angina pectoris; cardiac re-occlusion by-pass; intermittent claudication (atheroschlerosis oblitterens), diastolic dysfunction, and / or systolic dysfunction;
    (Ix) the prevention and / or treatment of gastrointestinal diseases, such as inflammatory bowel syndrome and small bowel syndrome or Crohn's disease, dyspepsia, and / or gastric ulcers;
    (X) the prevention and / or treatment of serious illnesses, such as the treatment of a critically ill patient, a critical polynephropathy disease (CIPNP) of the patient, and / or a potential CIPNP patient, disease prevention or the development of CIPNP criticism; prevention, treatment and / or cure of systemic inflammatory response syndrome (SIRS) in a patient, and / or for the prevention or reduction of the risk of a patient suffering from bacteremia, septicemia, and / or during hospitalization, septic shock and / or;
    (Xi) the prevention and / or treatment of polycystic ovary syndrome (PCOS).
    [00057] In a particular mode, the indication is selected from the group consisting of (i) - (iii) and (v) - (iix), such as indications (i), (ii), and / or (iii ), or an indication (v), an indication (vi), an indication (VII), and / or an indication (iix). In another particular mode, the indication is (i). In another particular mode, the indication is (v). In an even more particular mode, the indication is (iix). In some embodiments the indications are type 2 diabetes and / or
    Petition 870190075717, of 06/08/2019, p. 34/57
    30/45 obesity
    Other Modalities
    1. Solid composition for oral administration, CHARACTERIZED by the fact that it comprises a GLP-1 agonist and an N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt, in which the amount of said N acid salt - Caprylic (8- (2-hydroxybenzoyl) amino) is at least 0.6 mmol.
    2. Solid composition for oral administration, CHARACTERIZED by the fact that it comprises a GLP-1 agonist and an N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt, in which the amount of said N acid salt - Caprylic (8- (2-hydroxybenzoyl) amino) is at least 0.8 mmol.
    Composition shape
    3. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition is in the form of a tablet.
    4. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the tablet has a weight in the range of 175 to 1000 mg.
    5. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the tablet has a weight in the range of 200 to 800 mg.
    6. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the tablet has a weight selected from the group consisting of 200 mg, such as 400 mg or 700 mg.
    7. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the tablet has a weight selected from the group consisting of 200 mg, 400 mg, 600 mg or 800 mg.
    Petition 870190075717, of 06/08/2019, p. 35/57
    31/45
    Sat of caprylic N- (8- (2-hydroxybenzoyl) amino) acid
    8. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said salt of caprylic N- (8- (2-hydroxybenzoyl) amino) acid comprises a monovalent cation, two monovalent cations or a divalent cation.
    9. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said salt of caprine N- (8- (2-hydroxybenzoyl) amino) acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of caprylic N- (8- (2-hydroxybenzoyl) amino) acid.
    10. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid is N- (8- (2-hydroxybenzoyl) amino) caprylate sodium (SNAC).
    Amount of N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt
    11. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the amount of said salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid is in the range of 0.6 to 2.1 mmol, such as 0.6 to 1.9 mmol, 0.7 to 1.7 mmol or 0.8 to 1.3 mmol.
    12. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the amount of said salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid is at least 0.6 mmol, as selected from the group consisting of at least 0.65 mmol, at least 0.7 mmol, at least 0.75 mmol, at least 0.8 mmol, at least 0.8 mmol, at least 0.9 mmol, at least 0.95 mmol and at least 1 mmol.
    13. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the amount of the
    Petition 870190075717, of 06/08/2019, p. 36/57
    32/45 said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is up to 2.1 mmol, as selected from the group consisting of up to 2.1 mmol, up to 2 mmol, up to 1 , 9 mmol, up to 1.8 mmol, up to 1.7 mmol, up to 1.6 mmol, up to 1.5 mmol, up to 1.4 mmol, up to 1.3 mmol, up to 1.2 mmol and up to 1.1 mmol.
    14. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the amount of said salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid is 1 mmol, as well as 1.08 mmol .
    15. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises at least 60% (weight / weight), such as, at least 70% (weight / weight) or at least 75% (weight / weight) of said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt.
    SNAC quantity
    16. Composition according to modality 10, CHARACTERIZED by the fact that the amount of SNAC is at least 175 mg, such as, an amount selected from the group consisting of at least 200 mg, at least 210 mg, at least 220 mg, at least 230 mg, at least 240 mg, at least 250 mg, at least 260 mg, at least 270 mg and at least 280 mg.
    17. Composition according to modality 10, CHARACTERIZED by the fact that the amount of SNAC is up to 575 mg, such as, an amount selected from the group consisting of up to 550 mg, up to 525 mg, up to 500 mg, up to 475 mg, up to 450 mg, up to 425 mg, up to 400 mg, up to 375 mg, up to 350 mg and up to 325 mg.
    18. Composition according to modality 10, CHARACTERIZED by the fact that the amount of SNAC is 300 mg. GLP-1
    19. Composition according to any of the modali
    Petition 870190075717, of 06/08/2019, p. 37/57
    33/45 previous activities, CHARACTERIZED by the fact that the amount of the GLP-1 agonist is in the range of 0.01 mg to 100 mg.
    20. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the GLP-1 agonist comprises a substituent.
    21. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said substituent comprises a fatty acid or a fatty diacid.
    22. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said substituent comprises a C16, C18 or C20 fatty acid.
    23. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said substituent comprises a C16, C18 or C20 fatty diacid.
    24. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said substituent comprises Formula (X)
    O (X), where n is at least 13, such as, n is 13, 14, 15, 16, 17, 18 or 19.
    25. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said substituent comprises one or more 8-amino-3,6-dioxaoctanoic acid (OEG), such as two OEG.
    26. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the GLP-1 agonist is GLP-1 (7-37), GLP-1 (7-36) amide, exendin-4 or an analogue of its own comprising up to 10 substitutions, deletions, additions and / or insertions, wherein said GLP-1 agonist optionally comprises
    Petition 870190075717, of 06/08/2019, p. 38/57
    34/45 addresses a substituent.
    27. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the GLP-1 agonist is GLP-1 (7-37), GLP-1 (7-36) amide, exendin-4 or an analogue of its own comprising up to 7 substitutions, deletions, additions and / or insertions, wherein said GLP-1 agonist optionally comprises a substituent.
    28. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the GLP-1 agonist is GLP-1 (7-37), GLP-1 (7-36) amide, exendin-4 or an analogue of its own comprising up to 4 substitutions, deletions, additions and / or insertions, wherein said GLP-1 agonist optionally comprises a substituent.
    29. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the GLP-1 agonist is GLP-1 (7-37), GLP-1 (7-36) amide, exendin-4 or an analogue of its own comprising up to 3 substitutions, deletions, additions and / or insertions, wherein said GLP-1 agonist optionally comprises a substituent.
    30. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the GLP-1 agonist is semaglutida.
    31. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the amount of the GLP-1 agonist is in the range of 1 to 20 mg, as well as, in the range of 5 to 20 mg, as well as, in the range from 5 to 15 mg, such as 10 mg.
    32. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the amount of GLP-1 is in the range of 0.05 to 25 pmol, as well as, in the range of 0.5 to 2.5 pmol.
    Petition 870190075717, of 06/08/2019, p. 39/57
    35/45
    Other excipients
    33. Composition according to any of the foregoing modalities, CHARACTERIZED by the fact that said composition comprises at least one additional pharmaceutically acceptable excipient.
    34. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said excipient is selected from one or more of the group consisting of binders, fillers, disintegrants and lubricants and / or glidants.
    35. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises from 0.1 to 10% (weight / weight), such as, from 0.2 to 4% (weight / weight) or 0.5 to 3% (weight / weight) of binder.
    36. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises 1% (weight / weight) or 2% (weight / weight) of binder.
    37. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said binder is povidone.
    38. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises from 5 to 40% (weight / weight), such as from 10 to 30% (weight / weight) or from 5 to 25% (weight / weight), filling.
    39. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises 10.9% (weight / weight) or 18% (weight / weight) of filling, or comprises 19.5% (weight / weight) weight) or 20.5 (weight / weight) of filling.
    Petition 870190075717, of 06/08/2019, p. 40/57
    36/45
    40. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said filling is avicel, such as avicel PH 102 or avicel PH 200.
    41. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises from 0.1 to 10% (weight / weight) or 0.5 to 5% (weight / weight) lubricant and / or a slider.
    42. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises from 1 to 3.5% (weight / weight) or 1% (weight / weight) lubricant and / or a glidant.
    43. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said excipient is magnesium stearate.
    44. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said composition comprises at least 60% (weight / weight) of release agent, less than 10% (weight / weight) of binder, of 5 to 40% (weight / weight) of filler, and less than 10% (weight / weight) of lubricant and / or glidant.
    Administration regime
    45. Use of the composition according to any of the previous modalities, CHARACTERIZED by the fact that the composition is administered orally.
    Functional characteristics
    46. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said tablet has surface erosion properties.
    47. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the referred with
    Petition 870190075717, of 06/08/2019, p. 41/57
    37/45 primido has co-release of the GLP-1 agonist and the release agent as determined by the current release test described here.
    48. Composition according to any of the previous modalities, CHARACTERIZED by the fact that the said tablet has a disintegration time in the range of 7 to 15 minutes as determined by the disintegration test described here.
    49. Composition according to any of the previous modalities, CHARACTERIZED by the fact that said tablet has a hardness of at least 50 N as determined by the hardness test described here.
    Use as a medicine
    50. Use of a composition as defined in any of the previous modalities, CHARACTERIZED pfact of being in medicine.
    51. Use of a composition as defined in any of the previous modalities, CHARACTERIZED by the fact that it is for the treatment of type 2 diabetes or obesity.
    52. Method for the treatment of type 2 diabetes or obesity, CHARACTERIZED by understanding the administration of a composition as defined in any of the previous modalities.
    Examples
    Example 1 [00058] The objective of the present study was to evaluate the bioavailability-oral ability in dogs of the beagle breed of a series of compositions that comprise semagglutida and SNAC.
    Method
    Animals, dosage and blood collection [00059] Twenty-four male and 24 female beagle dogs, weighing 6-11 kg during the study period were included
    Petition 870190075717, of 06/08/2019, p. 42/57
    38/45 in the study. The dogs were dosed under fasting conditions. The compositions were administered by a single oral dose to dogs, in groups of four males and four females. Blood samples were taken at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 24, 48 , 72, 96, 120, 144, 192 and 240 hours after administration.
    [00060] The intravenous solution (20 nmol / mL in a pH 7.4 solution containing 0.1 mg / mL Tween 20, 5.5 mg / mL phenol, 1.42 mg / mL Na2HPO4 and 14 mg / mL of propylene glycol) was dosed in a dose volume of 0.1 mL / kg in the same colo-ny dog in a dosing group (n = 8). Blood samples were taken at the following time points: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 24, 48 , 72, 96, 120, 144, 192 and 240 hours after administration. Plasma Preparation [00061] All blood samples were collected in test tubes containing EDTA for stabilization and kept on ice until centrifugation. Plasma was separated from whole blood by centrifugation and the plasma was stored at -20 ° C or below, until analysis. Plasma sample analysis [00062] Plasma was analyzed for semagglutide using an Oxygen Immunoassay Canalization (loci) luminescence. The LOCI assay employs donor beads coated with streptavidin and recipient beads conjugated with a link to the center-molecular region of semagglutide monoclonal antibody. The other monoclonal antibody, specific for an N-terminal epitope, was biotinylated. In the assay the three reagents were combined with which two localized immuno-complexes form a semagglutide. The illumination of the complex singlet releases oxygen atoms from the donor spheres that channels to the acceptor spheres and chemiluminescence trigger that was measured on the EnVision plate reader. The amount of light is
    Petition 870190075717, of 06/08/2019, p. 43/57
    39/45 proportional to the concentration of semagglutide and the lower limit of quantification (LLOQ) in plasma was 100 pM.
    Analysis of Compositions [00063] The amount of semagglutide and SNAC in the composition were as-Sayed using a reverse phase HPLC method, with UV detection at 230 nm, a linear gradient of mobile phase composed of deionized H2O: trifluoroacetic acid (TFA) (1000: 1) (v / v) (A) and acetonitrile: TFA (1000: 1) (v / v) (B).
    Pharmacokinetic calculations [00064] Semaglutida plasma concentration data were subjected to non-compartmental pharmacokinetic analysis using PC-based software Win-Nonlin, v 5.2 (Pharsight, Mountain View, CA. 94041, USA). For each dog, the maximum plasma concentration (Cmax) and the time to maximum plasma concentration (Tmax) were read from the plasma time concentration curves. The following pharmacokinetic parameters were estimated: Area Under Curve to infinity (AUCinf) and AUCinf / Dose (AUCinf / D). Bioavailability (F) was calculated as the absorbed fraction (in%) based on the standardized dose AUC (AUCinf / D) after oral and intravenous administration. Statistical summary of pharmacokinetic results were presented as arithmetic mean, with calculated standard deviation, also for Tmax and plasma half-life.
    Table 1. Composition of the tablet expressed as per tablet
    Composition THE B Ç D AND F Semagglutide (mg) 10 10 10 5 15 20 SNAC (mg) 150 300 600 300 300 300 Povidone (mg) 2 4 7 3.5 4 4 Extragra- Avicel PHnull 102 (mg) 36 82 76 38 77 72
    Petition 870190075717, of 06/08/2019, p. 44/57
    40/45
    StearateMagnesium(mg) 2 4 7 3.5 4 4 Tablet Weight (mg) 200 400 700 350 400 400
    [00065] Semagglutide was prepared according to the method described in WO2006 / 097537, Example 4, and subsequently freeze-dried. SNAC was pre-stopped according to the method described in WO2008 / 028859. The compositions were prepared using the following manufacturing process:
    1) The ingredients were selected first through a No. 35 mesh;
    2) semagglutida and SNAC were geometrically mixed in a mortar and pestle;
    3) Povidone was dissolved in water and the resulting solution was used to granulate the mixture of semagglutide and SNAC;
    4) The granules were dried at a temperature not exceeding 40 ° C at a level of 4% humidity <; and
    5) The resulting dry granules were ground using a No. 35 mesh;
    6) Finally, the granules were mixed with the additional granular ingredients (see Table 1) and the final mixture was compressed into tablets, in which the compression was carried out at a pressure of about 4.4 kN or higher.
    [00066] The hardness of the tablet was more than 50 N as determined by the Pharma Test (33AA02), which measures the force required to break the tablet and the test is based on the Ph Eur pharmacopeia method. 2.9.8.
    Results
    Table 2. Summary of pharmacokinetic parameters for semagglutide from the single dosage of the tablets comprising 10 mg of
    Petition 870190075717, of 06/08/2019, p. 45/57
    41/45 semagglutide in combination with 150 mg (A), 300 mg (B) or 600 mg (C) SNAC.
    Composition SNAC (mg) T max (h) C max (pM) AUCinf / D F (%) THE 150 0.6 6222 0.62 0.17 B 300 0.8 21871 2,335 0.63 Ç 600 1.1 9972 1.09 0.29
    [00067] Individual calculated pharmacokinetic parameters and mean (SD) after oral dose appear in Tables 3-5 and after intravenous administration administration appear in Table 6.
    Table 3. The pharmacokinetic parameters for semagglutide after oral dosing for oral administration of a combination of 10 mg and 150 mg semagglutide SNAC (Composition A) to 4 of 4 male and female Beagle dogs.
    Dog No. Dose(nmol / kg) T max (h) C max (pM) AUCinf / D(h * kg * pmol / l / pmol) F (%) 1025 285 1.5 38300 4.08 1.1 1026 548 at. 0 0 0 1027 278 0.2 228 0 0.00003 1028 338 2.0 3410 0.31 0.08 1029 246 at. 0 0 0 1030 244 0.2 2030 0.07 0.02 1031 223 at. 0 0 0 1032 254 0.5 5810 0.47 0.13 Average 302 0.6 6222 0.62 0.17 SD 105 0.5 13130 1.41 0.38
    n.a.) not analyzed
    Table 4. The pharmacokinetic parameters for semagglutide after oral dosing for oral administration of a combination of 10 mg and
    Petition 870190075717, of 06/08/2019, p. 46/57
    42/45
    300 mg semagglutide SNAC (Composition B) and 4 male and 4 female Beagle dogs.
    Dog No. Dose(nmol / kg) T max (h) C max (pM) AUCinf / D(h * kg * pmol / l / pmol) F (%) 1033 294 0.5 5540 0.35 0.09 1034 301 2.0 72000 6.83 1.8 1035 276 at. 0 0 0 1036 258 1.5 21100 2.52 0.68 1037 239 2.0 70000 8.73 2.3 1038 261 0.7 4050 0.28 0.07 1039 223 0.5 2010 0.07 0.02 1040 249 0.2 271 0.00 0.0001 Average 263 0.8 21871 2.35 0.63 SD 26.7 0.5 31061 3.49 0.94
    n.a.) not analyzed
    Table 5. Pharmacokinetic parameters for semagglutide following the oral dosage of the combination of 10 mg semaglutide and 600 mg SNAC (Composition C) for beagle dogs 4 males and 4 females.
    Dog No. Dose(nmol / kg) T max (h) C max (pM) AUCinf / D(h * kg * pmol / l / pmol) F (%) 1041 262 at, 0 0 0 1042 278 0.5 1890 0.52 0.14 1043 265 3.0 261 0 0.0005 1044 265 0.7 1270 0.02 0.01 1045 251 1.5 48400 5.2 1.4 1046 285 2.0 22900 2.53 0.68 1047 226 0.7 4100 0.4 0.11 1048 248 0.7 953 0.01 0.004
    Petition 870190075717, of 06/08/2019, p. 47/57
    43/45
    Average 260 1.1 9972 1.09 0.29 SD 18 0.5 17298 1.87 0.50
    n.a.) not analyzed
    Table 6. Pharmacokinetic parameters for semagglutide following the intravenous dosage of 2 nmol / kg semaglutide for 4 male and 4 female beagles.
    Dog No. Dose(nmol / kg) T max (h) Cmax (pM) AUCinf / D(h * kg * pmol / l / pmol) 1065 1980 0.5 31400 310 1066 1980 0.2 17400 227 1067 1980 0.2 28300 385 1068 1980 4.0 12900 384 1069 1980 0.2 28300 398 1070 1980 0.2 27400 383 1071 1980 0.2 31000 472 1072 1980 0.2 25700 418 Average 1980 0.8 25300 372 SD 0 1.3 6638 73.8
    n.a.) not analyzed
    Table 7. Summary of pharmacokinetic parameters for semagglutide from the single dosage of the composition comprising 300 mg SNAC in combination with 5, 10, 15 or 20 mg semaglutide.
    Composition SNAÇ(mg) Semagglutide (mg) Tmax(H) Cmax(pM) AUCinf / D F (%) D 300 5 0.5 4446 1.22 0.33 B 300 10 0.8 21871 2.33 0.63 AND 300 15 1.0 42612 4.61 1.2 F 300 20 1.3 9603 5.09 1.4
    Petition 870190075717, of 06/08/2019, p. 48/57
    44/45
    Table 8. Pharmacokinetic parameters for semagglutide following the oral dosage of the combination of 5 mg semaglutide and 300 mg SNAC (Composition D) for 4 male and 4 female beagles.
    Dog No. Dose(nmol / kg) T max (h) C max (pM) AUCinf / D(h * kg * pmol / l / pmol) F (%) 1049 123 1 4490 1.54 0.41 1050 153 0.7 4420 0.5 0.13 1051 114 1 1720 4.27 1.1 1052 131 0.2 2390 0.52 0.14 1053 119 0.5 1860 0.31 0.08 1054 131 0.2 575 0.03 0.01 1055 113 0.7 3210 0.45 0.12 1056 107 0.5 1420 2.16 0.58 Average 124 0.5 4446 1.22 0.33 SD 15 0.5 5335 1.42 0.38
    Table 9. Pharmacokinetic parameters for semagglutide following the oral dosage of the combination of 15 mg semaglutide and 300 mg SNAC (Composition E) for 6 beagle dogs.
    Dog No. Dose(nmol / kg) T max (h) C max (pM) AUCinf / D(h * kg * pmol / l / pmol) F (%) 1067 318 1 56500 5.18 1.4 1068 393 1.5 61000 4.75 1.3 1069 322 1 15100 1.23 0.3 1070 341 0.5 2090 0 0.01 1071 283 2.5 11400 16.00 4.3 1072 312 0.5 6980 0.47 0.1 Average 328 1.0 42612 4.61 1.2 SD 37 0.8 43118 6.00 1.6
    Petition 870190075717, of 06/08/2019, p. 49/57
    45/45
    Table 10. Pharmacokinetic parameters for semagglutide following the oral dosage of the combination of 20 mg semaglutide and 300 mg SNAC (Composition F) for 4 male and 4 female beagles.
    Dog No. Dose(nmol / kg) T max (h) C max (pM) AUCinf / D(h * kg * pmol / l / pmol) F (%) 1057 588 1 197000 9.60 2.6 1058 619 1.5 144000 7.11 1.9 1059 508 1.5 77400 4.45 1.2 1060 519 1.5 91900 5.18 1.4 1061 519 2 70400 4.72 1.3 1062 519 1.5 155000 9.09 2.4 1063 460 0.7 1620 0.01 0.004 1064 487 1.5 11500 0.61 0.16 Average 527 1.3 93603 5.09 1.4 SD 52 0.5 68667 3.52 0.95
    Conclusion [00068] Surprisingly, tablets comprising 300 mg SNAC showed improved bioavailability in the current study over tablets comprising 150 mg or 600 mg SNAC.
    权利要求:
    Claims (17)
    [1]
    1. Solid composition for oral administration, characterized by the fact that it comprises a GLP-1 agonist and an N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt, the amount of which referred to the N- (8- (2-hydroxybenzoyl) amino) caprylic is at least 0.6 or at least 0.8 mmol; and said GLP-1 agonist being semagglutinated.
    [2]
    2. Solid composition for oral administration, characterized by the fact that it comprises a GLP-1 agonist and a salt of caprine N- (8- (2-hydroxybenzoyl) amino) acid, and which comprises at least 60% (w / w ), such as at least 70% (w / w) or at least 75% (w / w) of said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt; and said GLP-1 agonist being semagglutinated.
    [3]
    3. Composition according to claim 1 or 2, characterized by the fact that it is in the form of a tablet.
    [4]
    Composition according to any one of claims 1 to 3, characterized in that said N (8- (2-hydroxybenzoyl) amino) caprylic acid salt comprises a monovalent cation, two monovalent cations or a divalent cation.
    [5]
    Composition according to any one of claims 1 to 3, characterized in that said salt of caprylic N (8- (2-hydroxybenzoyl) amino) acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of caprylic N- (8- (2-hydroxybenzoyl) amino) acid.
    [6]
    Composition according to any one of claims 1 to 5, characterized in that the amount of said salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid is in the range of 0.6 to 2, 1 mmol, such as 0.6 to 1.9 mmol, 0.7 to 1.7 mmol or 0.8 to 1.3 mmol.
    [7]
    7. Composition according to any one of the claims
    Petition 870190075717, of 06/08/2019, p. 51/57
    2/3 cations 1 to 6, characterized by the fact that said salt of N (8- (2-hydroxybenzoyl) amino) caprylic acid is sodium N- (8- (2-hydroxybenzoyl) amino) caprylate (SNAC).
    [8]
    8. Composition according to any one of claims 1 to 7, characterized by the fact that the amount of SNAC is at least 175 mg, such as a quantity selected from the group consisting of at least 200 mg, at least 210 mg, at least 220 mg, at least 230 mg, at least 240 mg, at least 250 mg, at least 260 mg, at least 270 mg and at least 280 mg.
    [9]
    9. Composition according to any one of the preceding claims 1 to 8, characterized by the fact that the amount of SNAC is up to 575 mg, such as a quantity selected from the group consisting of up to 550 mg, up to 525 mg, up to 500 mg, up to 475 mg, up to 450 mg, up to 425 mg, up to 400 mg, up to 375 mg, up to 350 mg and up to 325 mg.
    [10]
    10. Composition according to any one of the preceding claims 1 to 9, characterized by the fact that the amount of SNAC is 300 mg.
    [11]
    11. Composition according to any one of claims 1 to 10, characterized in that the amount of the GLP-1 agonist is in the range of 0.01 mg to 100 mg.
    [12]
    12. Composition according to any one of claims 1 to 11, characterized in that the amount of the GLP-1 agonist is in the range of 1 to 20 mg, as in the range of 5 to 20 mg, as in range of 5 to 15 mg.
    [13]
    13. Composition according to any one of claims 1 to 12, characterized by the fact that the amount of GLP-1 is in the range of 0.05 to 25 pmol, as well as, in the range of 0.5 to 2.5 pmol.
    [14]
    14. Composition according to any one of claims 1 to 13, characterized by the fact that the tablet has
    Petition 870190075717, of 06/08/2019, p. 52/57
    3/3 a weight in the range of 175 to 1000 mg, such as in the range of 200 to 800 mg.
    [15]
    Composition according to any one of claims 1 to 14, characterized in that it comprises at least one additional pharmaceutically acceptable excipient.
    [16]
    16. Use of a composition, as defined in any of claims 1 to 15, characterized by the fact that it is in medicine.
    [17]
    17. Composition according to any one of claims 1 to 15, characterized by the fact that it is for the treatment of type II diabetes or obesity.
    类似技术:
    公开号 | 公开日 | 专利标题
    US10960052B2|2021-03-30|Solid compositions comprising a GLP-1 agonist and a salt of N-| amino) caprylic acid
    US20200000728A1|2020-01-02|Solid compositions comprising a glp-1 agonist and a salt of n-|amino)caprylic acid
    IL277857D0|2020-11-30|Solid compositions comprising a glp-1 agonist and a salt of n-|amino)caprylic acid
    ES2793423T3|2020-11-13|Solid compositions comprising a GLP-1 agonist and a salt of N- | amino) caprylic acid
    TW202114730A|2021-04-16|Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-|amino)caprylic acid
    CA3144611A1|2021-02-11|Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-|amino)caprylic acid
    同族专利:
    公开号 | 公开日
    DK2651398T3|2018-03-12|
    AU2011343190A1|2013-06-06|
    BR112013014942A2|2017-05-30|
    RS60321B1|2020-07-31|
    SI3326620T1|2020-07-31|
    CN105963685A|2016-09-28|
    SI2651398T1|2018-04-30|
    HRP20180425T1|2018-04-20|
    WO2012080471A1|2012-06-21|
    EP3326620B1|2020-03-04|
    US9278123B2|2016-03-08|
    KR20140030116A|2014-03-11|
    US10960052B2|2021-03-30|
    LT2651398T|2018-03-26|
    US20160151462A1|2016-06-02|
    US20210177944A1|2021-06-17|
    EP3326620A1|2018-05-30|
    CA2821886A1|2012-06-21|
    EP2651398A1|2013-10-23|
    JP2014503526A|2014-02-13|
    CN103260608A|2013-08-21|
    KR101925620B1|2018-12-05|
    MX2013006171A|2013-07-15|
    HUE036066T2|2018-06-28|
    MX345501B|2017-02-02|
    ES2661676T3|2018-04-03|
    RU2600440C2|2016-10-20|
    AU2011343190B2|2016-12-08|
    JP5902194B2|2016-04-13|
    JP2016117759A|2016-06-30|
    RU2013131913A|2015-01-27|
    PL2651398T3|2018-05-30|
    RU2600440C3|2021-12-10|
    RS56998B1|2018-05-31|
    EP2651398B1|2017-12-13|
    US20180360918A1|2018-12-20|
    CN105963685B|2021-01-15|
    DK3326620T3|2020-05-25|
    PL3326620T3|2020-08-24|
    PT2651398T|2018-03-09|
    US10086047B2|2018-10-02|
    US20130345134A1|2013-12-26|
    EP3730127A1|2020-10-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP0238259B1|1986-03-12|1993-09-29|American Cyanamid Company|Macrolide compounds|
    AT164852T|1990-01-24|1998-04-15|Douglas I Buckley|GLP-1 ANALOG USES IN DIABETE TREATMENT|
    US5545618A|1990-01-24|1996-08-13|Buckley; Douglas I.|GLP-1 analogs useful for diabetes treatment|
    DK39892D0|1992-03-25|1992-03-25|Bernard Thorens|PEPTIDE|
    US5705483A|1993-12-09|1998-01-06|Eli Lilly And Company|Glucagon-like insulinotropic peptides, compositions and methods|
    EP0803255A4|1994-06-03|1999-06-30|Tsumura & Co|Medicinal composition|
    US5512549A|1994-10-18|1996-04-30|Eli Lilly And Company|Glucagon-like insulinotropic peptide analogs, compositions, and methods of use|
    US5869602A|1995-03-17|1999-02-09|Novo Nordisk A/S|Peptide derivatives|
    US5866536A|1995-03-31|1999-02-02|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5650386A|1995-03-31|1997-07-22|Emisphere Technologies, Inc.|Compositions for oral delivery of active agents|
    SE9600070D0|1996-01-08|1996-01-08|Astra Ab|New oral pharmaceutical dosage forms|
    US6268343B1|1996-08-30|2001-07-31|Novo Nordisk A/S|Derivatives of GLP-1 analogs|
    KR100556067B1|1996-08-30|2006-03-07|노보 노르디스크 에이/에스|Glp-1 derivatives|
    US7235627B2|1996-08-30|2007-06-26|Novo Nordisk A/S|Derivatives of GLP-1 analogs|
    US6458924B2|1996-08-30|2002-10-01|Novo Nordisk A/S|Derivatives of GLP-1 analogs|
    AT289517T|1996-11-12|2005-03-15|Novo Nordisk As|USE OF GLP-1 PEPTIDES|
    US5773647A|1997-02-07|1998-06-30|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    EP1060191B1|1998-02-27|2010-04-28|Novo Nordisk A/S|Derivatives of glp-1 analogs|
    AT466028T|1998-02-27|2010-05-15|Novo Nordisk As|N-TERMINAL CHANGED GLP-1 ABÖMMLINGE|
    WO1999043705A1|1998-02-27|1999-09-02|Novo Nordisk A/S|N-terminally truncated glp-1 derivatives|
    EP1056775B1|1998-02-27|2010-04-28|Novo Nordisk A/S|Glp-1 derivatives of glp-1 and exendin with protracted profile of action|
    JP2002504518A|1998-02-27|2002-02-12|ノボノルディスクアクティーゼルスカブ|GLP-1 derivatives with helix-content of more than 25% forming partially structured micellar-like aggregates|
    SE9802080D0|1998-06-11|1998-06-11|Hellstroem|Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein|
    EP1932535A3|1998-07-31|2008-10-29|Novo Nordisk A/S|Stimulation of beta cell profileration|
    MY155270A|1998-09-24|2015-09-30|Lilly Co Eli|Use of glp-1 or analogs in treatment of stroke|
    AT282635T|1998-12-07|2004-12-15|Sod Conseils Rech Applic|GLP-1 ANALOG|
    CA2361716C|1999-02-05|2009-04-28|Emisphere Technologies, Inc.|Method of preparing alkylated salicylamides|
    CA2363123C|1999-02-22|2011-09-06|Kenneth Iain Cumming|Solid oral dosage form containing an enhancer|
    AU3240900A|1999-02-22|2000-09-04|Emisphere Holdings, Inc.|Solid oral dosage form containing heparin or a heparinoid in combination with a carrier|
    US7658938B2|1999-02-22|2010-02-09|Merrion Reasearch III Limited|Solid oral dosage form containing an enhancer|
    AU775063C|1999-04-30|2005-05-12|Amylin Pharmaceuticals, Inc.|Modified exendins and exendin agonists|
    CA2363712C|1999-05-17|2011-05-10|Conjuchem Inc.|Long lasting insulinotropic peptides|
    EP1076066A1|1999-07-12|2001-02-14|Zealand Pharmaceuticals A/S|Peptides for lowering blood glucose levels|
    GB9923436D0|1999-10-04|1999-12-08|American Home Prod|Pharmaceutical compositions|
    US6793934B1|1999-12-08|2004-09-21|Shire Laboratories, Inc.|Solid oral dosage form|
    AU7523101A|2000-06-02|2001-12-11|Emisphere Tech Inc|Method of preparing salicylamides|
    US7049283B2|2000-12-06|2006-05-23|Novartis Ag|Pharmaceutical compositions for the oral delivery of pharmacologically active agents|
    NZ525577A|2000-12-07|2005-05-27|Lilly Co Eli|Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus|
    US7199217B2|2000-12-13|2007-04-03|Eli Lilly And Company|Amidated glucagon-like peptide-1|
    US20030068356A1|2001-07-10|2003-04-10|Pather S. Indiran|Sequential drug delivery systems|
    EP2022505B1|2001-07-31|2011-12-14|The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services|GLP-1, exendin-4, peptide analogs and uses thereof|
    EP1461031B1|2001-11-29|2016-06-29|Emisphere Technologies, Inc.|Formulations for oral administration of cromolyn sodium|
    MXPA04007427A|2002-02-01|2004-10-11|Pfizer Prod Inc|Dry granulated formulations of azithromycin.|
    KR101165431B1|2002-02-20|2012-07-12|에미스페어 테크놀로지스, 인코포레이티드|Method for administering glp-1 molecules|
    MXPA04012497A|2002-07-04|2005-07-14|Zealand Pharma As|Glp-1 and methods for treating diabetes.|
    JP2004131398A|2002-10-08|2004-04-30|Taihei Chemical Industrial Co Ltd|Lubricant for tablet|
    WO2004067548A2|2003-01-31|2004-08-12|Theratechnologies Inc.|Chemically modified metabolites of regulatory peptides and methods of producing and using same|
    PT1605897E|2003-03-19|2012-09-10|Lilly Co Eli|Polyethelene glycol link glp-1 compounds|
    JP2006528982A|2003-05-14|2006-12-28|エミスフェアー・テクノロジーズ・インク|Composition for delivery of peptide YY and PYY agonists|
    CN1809377B|2003-07-11|2010-08-04|诺瓦提斯公司|Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form|
    EP1653996A2|2003-08-08|2006-05-10|Novo Nordisk Health Care AG|Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest|
    KR101241862B1|2003-09-19|2013-03-13|노보 노르디스크 에이/에스|Novel glp-1 derivatives|
    BRPI0416743A|2003-11-20|2007-01-16|Novo Nordisk As|pharmaceutical formulation, and methods of preparing a suitable peptide formulation for use in an injection device, to reduce deposits in production equipment and the final product, and to reduce clogging of injection devices by a peptide formulation.|
    MXPA06006745A|2003-12-18|2006-08-18|Novo Nordisk As|Novel glp-1 compounds.|
    EP1696962A2|2003-12-18|2006-09-06|Novo Nordisk A/S|Novel glp-1 analogues linked to albumin-like agents|
    US20060286129A1|2003-12-19|2006-12-21|Emisphere Technologies, Inc.|Oral GLP-1 formulations|
    US20080318861A1|2005-12-08|2008-12-25|Nastech Pharmaceutical Company Inc.|Mucosal Delivery of Stabilized Formulations of Exendin|
    WO2005099672A1|2004-04-13|2005-10-27|Ranbaxy Laboratories Limited|A modified release pharmaceutical formulation comprising amoxicillin and clavulanate|
    SG153039A1|2004-05-06|2009-06-29|Emisphere Tech Inc|Crystalline polymorphic forms of monosodium n-[8- amino]caprylate|
    WO2005107773A2|2004-05-06|2005-11-17|Emisphere Technologies, Inc.|Solid dosage form of wetted heparin|
    EP1756039B1|2004-05-14|2012-10-17|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    WO2005121090A1|2004-06-02|2005-12-22|Abbott Laboratories|Substituted piperidines that have antiangiogenic activity|
    CN101010339B|2004-07-02|2011-11-09|布里斯托尔-迈尔斯斯奎布公司|Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions|
    WO2006005667A2|2004-07-08|2006-01-19|Novo Nordisk A/S|Polypeptide protracting tags comprising a tetrazole moiety|
    US20060078622A1|2004-08-13|2006-04-13|Emisphere Technologies, Inc.|Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent|
    JP5107713B2|2004-10-07|2012-12-26|ノヴォノルディスクアー／エス|Delayed exendin-4 compound|
    WO2006037810A2|2004-10-07|2006-04-13|Novo Nordisk A/S|Protracted glp-1 compounds|
    BRPI0517163A|2004-12-09|2008-09-30|Radial Corp Ltd|material handling for radial wood sawdust|
    JP5175553B2|2005-02-01|2013-04-03|エミスフェアー・テクノロジーズ・インク|Gastric retention and controlled release delivery system|
    EP1846446B1|2005-02-02|2013-06-26|Novo Nordisk A/S|Insulin derivatives|
    WO2006096515A2|2005-03-04|2006-09-14|Biorexis Pharmaceutical Corporation|Modified transferrin fusion proteins|
    JP2008533104A|2005-03-18|2008-08-21|ノボ ノルディスク アクティーゼルスカブ|GLP-1 receptor dimer peptide agonist|
    TWI362392B|2005-03-18|2012-04-21|Novo Nordisk As|Acylated glp-1 compounds|
    WO2006097535A2|2005-03-18|2006-09-21|Novo Nordisk A/S|Peptide agonists of the glucagon family with secretin like activity|
    RU2007134155A|2005-03-18|2009-04-27|Ново Нордиск А/С |GLP-1 INCREASED HALF-TIME COMPOUNDS|
    US20080260818A1|2005-03-28|2008-10-23|Dexcel Pharma Technologies Ltd.|Controlled Absorption of Statins in the Intestine|
    TW200716679A|2005-05-26|2007-05-01|Squibb Bristol Myers Co|N-terminally modified GLP-1 receptor modulators|
    AU2006283517B2|2005-08-19|2010-12-02|Amylin Pharmaceuticals, Llc|Exendin for treating diabetes and reducing body weight|
    US20070049557A1|2005-08-24|2007-03-01|Hashim Ahmed|Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers|
    WO2007061434A2|2005-11-10|2007-05-31|Nastech Pharmaceutical Company Inc.|A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome|
    CA2626933C|2005-11-17|2015-12-29|Novartis Ag|Pharmaceutical composition|
    EP2526950A1|2006-04-07|2012-11-28|Merrion Research III Limited|Solid oral dosage form containing an enhancer|
    WO2007121318A2|2006-04-12|2007-10-25|Emisphere Technologies, Inc.|Formulations for delivering insulin|
    BRPI0712041A2|2006-05-09|2011-12-27|Novo Nordisk As|insulin derivative|
    JP2009539862A|2006-06-09|2009-11-19|メリオンリサーチＩｉｉリミテッド|Solid oral dosage form with toughener|
    EP2040718B1|2006-06-28|2017-12-27|Emisphere Technologies, Inc.|Gallium nitrate formulations|
    ES2296529B1|2006-08-07|2009-04-01|Laboratorios Farmaceuticos Rovi, S.A.|PHARMACEUTICAL COMPOSITION WITH ABSORPTION PROMOTERS.|
    WO2008023050A1|2006-08-25|2008-02-28|Novo Nordisk A/S|Acylated exendin-4 compounds|
    EP2064175B1|2006-09-07|2014-08-06|F. Hoffmann-La Roche AG|A process for the manufacture of snac |
    PE20080840A1|2006-09-13|2008-08-27|Smithkline Beecham Corp|METHODS FOR ADMINISTERING LONG-LIVED HYPOGLYCEMIANT AGENTS|
    PE20080845A1|2006-09-22|2008-08-13|Novartis Ag|METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS|
    US20100069410A1|2006-12-01|2010-03-18|Emisphere Technologies Inc.| acyclovir formulations|
    AT507818T|2007-03-02|2011-05-15|Novartis Ag|ORAL ADMINISTRATION OF A CALCITONIN|
    WO2008145728A1|2007-06-01|2008-12-04|Novo Nordisk A/S|Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier|
    US8835381B2|2007-06-12|2014-09-16|Glaxosmithkline Llc|Methods for detecting protein in plasma|
    CA2697504A1|2007-08-29|2009-03-12|The Regents Of The University Of California|Salicylanilide modified peptides for use as oral therapeutics|
    JP2010538049A|2007-09-05|2010-12-09|ノボ・ノルデイスク・エー／エス|Cleaved GLP-1 derivatives and therapeutic uses thereof|
    CN101842109B|2007-09-05|2014-01-29|诺沃-诺迪斯克有限公司|Peptides derivatized with A-B-C-D- and their therapeutical use|
    EP2190872B1|2007-09-05|2018-03-14|Novo Nordisk A/S|Glucagon-like peptide-1 derivatives and their pharmaceutical use|
    MX2010003979A|2007-10-16|2010-06-02|Biocon Ltd|An orally administerable solid pharmaceutical composition and a process thereof.|
    JP5555634B2|2007-11-02|2014-07-23|エミスフェアテクノロジーズインコーポレイティッド|Method for treating vitamin B12 deficiency|
    US20090124639A1|2007-11-06|2009-05-14|Emisphere Technologies Inc.| valacyclovir formulations|
    US20100317057A1|2007-12-28|2010-12-16|Novo Nordisk A/S|Semi-recombinant preparation of glp-1 analogues|
    NZ591497A|2008-08-18|2012-11-30|Entera Bio Ltd|A compositions comprising a protein, a protease inhibitor and N-caprylate or N-decanoate for diabetes mellitus treatment|
    CN102149411A|2008-09-12|2011-08-10|诺沃—诺迪斯克有限公司|Method of acylating a peptide or protein|
    DK2386203T3|2008-10-15|2014-02-24|Bayer Cropscience Ag|Use of dithiin-tetracarboximider for the control of phytopathogenic fungi|
    CN101463081B|2009-01-12|2012-07-04|华东师范大学|GLP-1 derivative|
    EP2395988A2|2009-02-13|2011-12-21|Boehringer Ingelheim International GmbH|Antidiabetic medications comprising a dpp-4 inhibitor optionally in combination with other antidiabetics|
    AR077956A1|2009-09-14|2011-10-05|Bayer Cropscience Ag|COMBINATIONS OF ACTIVE COMPOUNDS|
    US20120329711A1|2009-12-16|2012-12-27|Nordisk A/S|Glp-1 receptor agonist compounds with a modified n-terminus|
    WO2011084618A2|2009-12-16|2011-07-14|Nod Pharmaceuticals, Inc.|Compositions and methods for oral drug delivery|
    US20110182985A1|2010-01-28|2011-07-28|Coughlan David C|Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof|
    WO2011109787A1|2010-03-05|2011-09-09|Conjuchem, Llc|Methods of administering insulinotropic peptides|
    WO2011116139A2|2010-03-16|2011-09-22|Chiasma Inc.|Improved pharmaceutical compositions and methods of delivery|
    AU2011245980A1|2010-04-30|2012-11-08|Sanwa Kagaku Kenkyusho Co., Ltd.|Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability|
    EP2566469A1|2010-05-05|2013-03-13|Boehringer Ingelheim International GmbH|Combination therapy|
    DE202010015867U1|2010-11-25|2011-05-05|Buchhalter, Thomas|Electromechanical holder for holding navigation and communication devices in the vehicle|
    PT2651398T|2010-12-16|2018-03-09|Novo Nordisk As|Solid compositions comprising a glp-1 agonist and a salt of n-amino)caprylic acid|
    PL2696687T3|2011-04-12|2017-06-30|Novo Nordisk A/S|Double-acylated glp-1 derivatives|
    US9382304B2|2011-07-08|2016-07-05|Amylin Pharmaceuticals, Llc|Engineered polypeptides having enhanced duration of action with reduced immunogenicity|
    ES2715308T3|2012-03-22|2019-06-03|Novo Nordisk As|Compositions comprising a supply agent and its preparation|
    WO2013139694A1|2012-03-22|2013-09-26|Novo Nordisk A/S|Compositions of glp-1 peptides and preparation thereof|
    CN111494323A|2012-03-22|2020-08-07|诺和诺德股份有限公司|Compositions comprising delivery agents and preparation thereof|
    WO2013189988A1|2012-06-20|2013-12-27|Novo Nordisk A/S|Tablet formulation comprising a peptide and a delivery agent|
    JP6059802B2|2012-07-01|2017-01-11|ノヴォ ノルディスク アー／エス|Use of long-acting GLP-1 peptide|
    MY172578A|2013-05-02|2019-12-03|Novo Nordisk As|Oral dosing of glp-1 compounds|
    CA2975676A1|2015-02-09|2016-08-18|Entera Bio Ltd.|Formulations for oral administration of active agents with controlled absorption profile|
    AU2016335287A1|2015-10-07|2018-04-12|Cyprumed Gmbh|Pharmaceutical formulations for the oral delivery of peptide drugs|
    RU2020127262A|2018-02-02|2022-02-14|Ново Нордиск А/С|SOLID COMPOSITIONS CONTAINING GLP-1 agonist, N-amino)caprylic acid SALT AND LUBRICANT|PT2651398T|2010-12-16|2018-03-09|Novo Nordisk As|Solid compositions comprising a glp-1 agonist and a salt of n-amino)caprylic acid|
    PL2696687T3|2011-04-12|2017-06-30|Novo Nordisk A/S|Double-acylated glp-1 derivatives|
    WO2013139694A1|2012-03-22|2013-09-26|Novo Nordisk A/S|Compositions of glp-1 peptides and preparation thereof|
    CN111494323A|2012-03-22|2020-08-07|诺和诺德股份有限公司|Compositions comprising delivery agents and preparation thereof|
    ES2715308T3|2012-03-22|2019-06-03|Novo Nordisk As|Compositions comprising a supply agent and its preparation|
    WO2013189988A1|2012-06-20|2013-12-27|Novo Nordisk A/S|Tablet formulation comprising a peptide and a delivery agent|
    JP6059802B2|2012-07-01|2017-01-11|ノヴォ ノルディスク アー／エス|Use of long-acting GLP-1 peptide|
    AR092925A1|2012-10-09|2015-05-06|Sanofi Sa|DERIVATIVES OF EXENDINA-4 AS DUAL AGONISTS OF GLP1 / GLUCAGON|
    CN104870009B|2012-12-21|2021-05-18|赛诺菲|Functionalized exendin-4 derivatives|
    CN105101950B|2013-03-05|2019-10-11|安特里斯生物制药公司|The drug of oral delivery|
    CN104055735B|2013-03-22|2016-08-03|深圳翰宇药业股份有限公司|A kind of liposome of Sa Molutai and preparation method thereof|
    MY172578A|2013-05-02|2019-12-03|Novo Nordisk As|Oral dosing of glp-1 compounds|
    TW201609796A|2013-12-13|2016-03-16|賽諾菲公司|Non-acylated EXENDIN-4 peptide analogues|
    TW201609795A|2013-12-13|2016-03-16|賽諾菲公司|EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists|
    TW201609797A|2013-12-13|2016-03-16|賽諾菲公司|Dual GLP-1/glucagon receptor agonists|
    WO2015086729A1|2013-12-13|2015-06-18|Sanofi|Dual glp-1/gip receptor agonists|
    TW201625669A|2014-04-07|2016-07-16|賽諾菲公司|Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4|
    TW201625670A|2014-04-07|2016-07-16|賽諾菲公司|Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4|
    TW201625668A|2014-04-07|2016-07-16|賽諾菲公司|Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists|
    WO2016120378A1|2015-01-29|2016-08-04|Novo Nordisk A/S|Tablets comprising glp-1 agonist and enteric coating|
    US9932381B2|2014-06-18|2018-04-03|Sanofi|Exendin-4 derivatives as selective glucagon receptor agonists|
    DK3006045T3|2014-10-07|2017-07-17|Cyprumed Gmbh|Pharmaceutical formulations for oral administration of peptide or protein drugs|
    CN105777872B|2014-12-16|2019-06-07|深圳翰宇药业股份有限公司|A kind of purification process of Sa Molu peptide|
    JP6910950B2|2015-01-12|2021-07-28|エンテリス・バイオファーマ・インコーポレイテッドＥｎｔｅｒｉｓ Ｂｉｏｐｈａｒｍａ，Ｉｎｃ．|Solid oral dosage form|
    CA2975676A1|2015-02-09|2016-08-18|Entera Bio Ltd.|Formulations for oral administration of active agents with controlled absorption profile|
    WO2016168388A2|2015-04-14|2016-10-20|Palatin Technologies, Inc.|Therapies for obesity, diabetes and related indications|
    AR105319A1|2015-06-05|2017-09-27|Sanofi Sa|PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR|
    AR105284A1|2015-07-10|2017-09-20|Sanofi Sa|DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS|
    CN108699126A|2016-03-03|2018-10-23|诺和诺德股份有限公司|GLP-1 derivatives and application thereof|
    CN109069589A|2016-04-28|2018-12-21|诺和诺德股份有限公司|Si Meilu peptide for the cardiovascular patient's condition|
    KR102223227B1|2016-09-26|2021-03-08|추가이 세이야쿠 가부시키가이샤|Pyrazolopyridine derivatives with GLP-1 receptor agonist action|
    WO2018200691A2|2017-04-25|2018-11-01|Proteus Digital Health, Inc.|Lisinopril compositions with an ingestible event marker|
    TW201904583A|2017-06-09|2019-02-01|丹麥商諾佛 儂迪克股份有限公司|Solid composition for oral administration|
    RU2020127262A|2018-02-02|2022-02-14|Ново Нордиск А/С|SOLID COMPOSITIONS CONTAINING GLP-1 agonist, N-amino)caprylic acid SALT AND LUBRICANT|
    TW202015722A|2018-05-07|2020-05-01|丹麥商諾佛 儂迪克股份有限公司|Solid compositions comprising a glp-1 agonist and a salt of n-amino)caprylic acid|
    CN113329810A|2019-01-24|2021-08-31|诺和诺德股份有限公司|Roller press and dry granulation method using the same|
    KR20210150436A|2019-04-10|2021-12-10|장피트|Combination therapy comprising a compound of formulaand a GLP-1 receptor agonist|
    WO2021023817A1|2019-08-07|2021-02-11|Novo Nordisk A/S|Solid composition comprising a pyy compound and a salt of n-amino)caprylic acid|
    WO2021023855A1|2019-08-07|2021-02-11|Novo Nordisk A/S|Solid compositions comprising an egf derivative and a salt of n-amino)caprylic acid|
    WO2021043803A1|2019-09-02|2021-03-11|Novo Nordisk A/S|Process for producing a tablet comprising glp-1 peptides|
    WO2021089761A1|2019-11-07|2021-05-14|Novo Nordisk A/S|Solid compositions comprising a pcsk9 inhibitor and a salt of n-amino)caprylic acid|
    WO2021089752A1|2019-11-07|2021-05-14|Novo Nordisk A/S|Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-amino)caprylic acid|
    WO2021219710A1|2020-04-29|2021-11-04|Novo Nordisk A/S|Solid compositions comprising a glp-1 agonist and histidine|
    KR20220012840A|2020-07-22|2022-02-04|노보 노르디스크 에이/에스|Co-agonists at GLP-1 and GIP receptors suitable for oral delivery|
    CN112062690A|2020-11-11|2020-12-11|北京先为达生物科技有限公司|Potassium N- [8-amino ] caprylate crystal polymorph and preparation method and application thereof|
    法律状态:
    2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2018-07-31| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2019-06-11| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|
    2019-11-19| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2020-01-28| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    EP10195285|2010-12-16|
    US201061425087P| true| 2010-12-20|2010-12-20|
    PCT/EP2011/073060|WO2012080471A1|2010-12-16|2011-12-16|Solid compositions comprising a glp-1 agonist and a salt of n-amino)caprylic acid|
    [返回顶部]